Compare Revvity Inc (RVTY) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs VNET Group Inc — how do they compare? Revvity Inc trades at $154.66 (market cap $16.98B), while VNET Group Inc trades at $5.48 (market cap $1.47B). The key difference: Revvity Inc is far larger — about 11.6× VNET Group Inc's market cap, and Revvity Inc pays a 0.18% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and VNET Group Inc for 16 Days on average.
| RVTY | VNET | |
|---|---|---|
Market Cap | $16.98B | $1.47B |
Volume | 1,456,900 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $157.36 | $14.03 |
52-Week Low | $82.26 | $5.13 |
Typical Hold Time | 12 Days | 16 Days |
Enterprise Value | $19.30B | $5.04B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
VNET trades at $5.46, up 1.3% today but near 52-week lows, with a bearish technical signal. The company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Recent news includes a strategic investment closing and a cooperation agreement with CATL, providing some positive catalysts amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst sentiment is moderately bullish with 62.5% buy ratings. Key risks include balance sheet strain from negative cash flow and competitive pressures in the data center market. Upside potential hinges on execution of new partnerships and demand for AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
